Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma

Inclusion Criteria:

* Differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma confirmed by pathology;
* The staging is T1-2N0-1M0 (except T1N0M0) (UICC 8th edition);
* Initial treatment patients who have not received anti-tumor therapy;
* No history of other malignant tumors;
* Male or female, aged 18 to 70 years old;
* Liver and kidney function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT ≤ 2.5 times ULN; alkaline phosphatase ≤ 5 times ULN; creatinine clearance ≥ 80 mL/min;
* Neutrophil count (ANC) ≥2×109/L, platelet count ≥100×109/L and hemoglobin ≥9 g/dL;
* No serious heart, lung, liver, kidney and other important organ dysfunction;
* Karnofsky score ≥70 points;
* Sign the informed consent form;
* Able to follow research protocols and follow-up procedures.

Exclusion Criteria:

* Anti-tumor treatment has been performed, including chemotherapy, radiotherapy, and surgery;
* Find distant metastases before treatment;
* Women who are pregnant or breastfeeding;
* Disagree to sign the informed consent form;
* Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographic reasons;
* Simultaneously accept experimental treatment of other clinical research (in the treatment period of clinical research);
* Known to be allergic to possible chemotherapy drugs;
* Patients with other malignant tumors;
* Accompanied by severe uncontrollable infections or medical diseases, including autoimmune diseases;
* Major organ dysfunction, such as decompensated heart, lung, kidney, and liver failure, cannot tolerate radiotherapy and chemotherapy;
* Laboratory examination: total bilirubin\>upper limit of normal (ULN); AST and/or ALT\>1.5 times ULN and accompanied by alkaline phosphatase\>2.5 times ULN;
* Any uncertain factors that affect patient safety or compliance.